Applied Therapeutics Says Path Forward Not Determined for Govorestat; Shares Fall Pre-Bell

MT Newswires Live

Sep 29

Applied Therapeutics (APLT) said Monday that a path forward for its new drug application for govorestat to treat Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency has not been determined.

The company said it completed a meeting with the US Food and Drug Administration to discuss the potential submission in Q3.

Applied Therapeutics said it is waiting for the official meeting minutes from the FDA to decide on the next steps.

Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency is a genetic metabolic disease.

Shares of Applied Therapeutics were down more than 60% in recent Monday premarket activity.

Price: 0.49, Change: -0.75, Percent Change: -60.51

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571216380"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571216380\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571216380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571216380","market":"nz","top_or_hot":-1,"title":"Applied Therapeutics Says Path Forward Not Determined for Govorestat; Shares Fall Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/AMAT\">Applied</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (APLT) said Monday that a path forward for its new drug application for govorestat to treat Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency has not been determined.</p><p>The company said it completed a meeting with the US Food and Drug Administration to discuss the potential submission in Q3.</p><p>Applied Therapeutics said it is waiting for the official meeting minutes from the FDA to decide on the next steps.</p><p>Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency is a genetic metabolic disease.</p><p>Shares of Applied Therapeutics were down more than 60% in recent Monday premarket activity.</p><p>Price: 0.49, Change: -0.75, Percent Change: -60.51</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied Therapeutics Says Path Forward Not Determined for Govorestat; Shares Fall Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied Therapeutics Says Path Forward Not Determined for Govorestat; Shares Fall Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-29 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/AMAT\">Applied</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (APLT) said Monday that a path forward for its new drug application for govorestat to treat Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency has not been determined.</p><p>The company said it completed a meeting with the US Food and Drug Administration to discuss the potential submission in Q3.</p><p>Applied Therapeutics said it is waiting for the official meeting minutes from the FDA to decide on the next steps.</p><p>Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency is a genetic metabolic disease.</p><p>Shares of Applied Therapeutics were down more than 60% in recent Monday premarket activity.</p><p>Price: 0.49, Change: -0.75, Percent Change: -60.51</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLT","symbol_name":"Applied Therapeutics Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2571216380","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571216380","pubTimestamp":1759146236,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Applied Therapeutics  said Monday that a path forward for its new drug application for govorestat to treat Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency has not been determined.The company said it completed a meeting with the US Food and Drug Administration to discuss the potential submission in Q3.Applied Therapeutics said it is waiting for the official meeting minutes from the FDA to decide on the next steps.Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency is a genetic metabolic disease.Shares of Applied Therapeutics were down more than 60% in recent Monday premarket activity.Price: 0.49, Change: -0.75, Percent Change: -60.51","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLT":"Applied Therapeutics Inc.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4145":"电子制造服务","BK4007":"制药","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4539":"次新股","LENZ":"Therapeutics","BK4202":"服装、服饰与奢侈品","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","FORD":"福沃德工业","BK4139":"生物科技"},"translate_title":"Applied Therapeutics表示Govorestat的前进道路尚未确定；盘前股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLT":1,"FORD":1.5,"LENZ":1.5},"content_text":"Applied Therapeutics (APLT) said Monday that a path forward for its new drug application for govorestat to treat Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency has not been determined.The company said it completed a meeting with the US Food and Drug Administration to discuss the potential submission in Q3.Applied Therapeutics said it is waiting for the official meeting minutes from the FDA to decide on the next steps.Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency is a genetic metabolic disease.Shares of Applied Therapeutics were down more than 60% in recent Monday premarket activity.Price: 0.49, Change: -0.75, Percent Change: -60.51","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}